Related Experiment Videos
[Intravenous gamma globulin in newborns]
1Unidad de Recién Nacidos y Cuidado Intensivo Neonatal, Hospital Militar Gorgas, Ancón, Panamá.
Revista Medica De Panama
|September 1, 1990
Summary
Intravenous immunoglobulin (IVIG) infusion is safe for stable newborns with bacterial infections. Monitoring showed no significant cardiopulmonary changes, with mild tachypnea in most infants during IVIG treatment.
Area of Science:
- Neonatal Medicine
- Immunology
Context:
- Bacterial infections pose significant risks to newborns.
- Intravenous immunoglobulin (IVIG) is used to manage various conditions in neonates.
- Assessing the safety and tolerance of IVIG in vulnerable infant populations is crucial.
Purpose:
- To evaluate the cardiopulmonary safety and tolerance of intravenous gammaglobulin (Sandoglobulina) infusion in newborns with bacterial infections.
Summary:
- Eight newborns received 3% IVIG at infusion rates of 0.5-1.5 mg/kg/min and 7-9 mg/kg/min.
- Cardiopulmonary parameters (heart rate, blood pressure, respiratory rate) were monitored.
- No significant changes in heart rate or blood pressure were observed.
- Mild tachypnea occurred in 7 of 8 infants, but all values remained within physiological ranges.
- Stable newborns with bacterial infections tolerated IVIG well at doses of 0.25 mg/kg/day to 1.0 gm/kg/day for 4-6 days.
Impact:
- This study supports the safety of using IVIG in neonates with bacterial infections.
- Provides evidence for tolerable infusion rates and dosages in this population.
- Informs clinical practice regarding IVIG administration in neonatal care.